Galera Therapeutics Completes Mergers; Establishes Contingent Value Rights

What Happened
Galera Therapeutics, Inc. (GRTX) filed an 8‑K on Aug 4, 2026 to report the closing of the previously announced mergers and related transactions. In connection with the closing, Parent and Legacy Obsidian entered into a Contingent Value Rights Agreement (CVR Agreement) dated Aug 3, 2026 with Equiniti Trust Company, LLC as Rights Agent, and the company plans to file a Form 15 after market close on Aug 3, 2026 to suspend its SEC reporting and terminate registration of Galera common stock under Section 12(g).

Key Details

• Record date: holders of Galera common stock of record as of July 31, 2026 will receive CVRs (one CVR per outstanding share for each category).
• CVR payouts: (1) one CVR entitles holders to a pro rata share of 80% of any future net proceeds from the Legacy Product for five years post‑closing; (2) one CVR entitles holders to a pro rata share of 95% of any future net proceeds from the Supportive‑Care Product Divestiture for ten years post‑closing.
• CVR mechanics: CVRs are contractual, not certificated or SEC‑registered, nontransferable except in limited circumstances, carry no voting/dividend rights, and pay no interest; payments, if any, will be distributed by the Rights Agent.
• Reporting/registration: the company intends to file Form 15 after the close of trading on Aug 3, 2026 to suspend reporting obligations under Sections 13(a) and 15(d); suspension is immediate upon filing and deregistration under Section 12(g) becomes effective 90 days later unless the SEC acts sooner.
• Corporate changes: the filing includes amended and restated certificate of incorporation and bylaws as exhibits and incorporates information about changes in control, the board and executive officers following the mergers.

Why It Matters
For retail investors, the filing signals that Galera has completed a transaction that changes the company's structure and public reporting status. Shareholders of record on July 31, 2026 will receive CVRs—contractual rights to potential future proceeds tied to specific products rather than ongoing stock ownership—so they should not expect voting rights, dividends, or guaranteed payments from those CVRs. The planned Form 15 filing means Galera will suspend SEC periodic reporting immediately and will be removed from Section 12(g) registration after the statutory period, reducing the public disclosure available to investors.